EGFR and cancer: However, in these cases, pulmonary toxicity could be due to MKIs’ peculiar mechanism of action (i.e. epidermal growth factor receptor inhibition on type II pneumocytes) (14), but also directly due to cancer (i.e. paraneoplastic syndrome) (15).